Safety of thalidomideBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6941.1437b (Published 28 May 1994) Cite this as: BMJ 1994;308:1437
- C L Crawford
- Department of Anatomy, Charing Cross and Westminster Medical School, London W6 8RF.
EDITOR, - Use of thalidomide only on a named patient basis does not necessarily mean that patients are protected from its side effects, as implied by Baroness Cumberlege, the junior health minister.1 According to Sir William Asscher, the former chairman of the Committee on the Safety of Medicines, “the companies who supply a drug for named patient use are not required by law …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial